Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose AZD3199 dry powder inhalation formulations in persistent asthma
2011-000133-37Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD3199 in asthma (3 arms), sponsored by AstraZeneca. Primary endpoints: FEV1 peak effect (Emax 0–24 h) and FEV1 trough effect (E22–26 h). Started Mar 2011; status: completed.
02
Drugs
AZD3199
03
Conditions
asthma
Beyond the preview
Go deeper on 2011-000133-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000133-37.